Save 40% over US generic Clolar prices.
Information about Clolar (Clofarabine)
Clolar is a brand name for clofarabine, a chemotherapy drug used primarily in the treatment of certain types of leukemia. It is a purine analog that interferes with DNA synthesis, thereby inhibiting the growth and proliferation of cancer cells.
Product Highlights
- Clolar is primarily indicated for the treatment of Acute Lymphoblastic Leukemia (ALL)
- Specifically in pediatric patients who have relapsed or are refractory to other treatments.
Key Ingredient
Key Benefits
- Shows effectiveness in treating relapsed or refractory ALL, particularly in children who have not responded to other therapies.
- The drug targets and destroys cancer cells by interfering with their DNA, which helps in controlling the disease.
- Clinical trials have demonstrated its potential in improving outcomes for patients with difficult-to-treat leukemia.
Direction of Use
- Clolar is administered via intravenous infusion. Dosage and administration schedules are typically determined by the patient's body weight and the specifics of their condition.
- Usually given in cycles, with the number of cycles and duration depending on individual patient response and tolerance.
Safety Concerns
- Common Side Effects: May include nausea, vomiting, diarrhea, fever, and fatigue. Hematologic toxicities such as neutropenia (low white blood cell count) and anemia are also common.
- Can cause severe infections due to immunosuppression, liver toxicity, and potential for tumor lysis syndrome.
- Regular blood tests and monitoring are required to manage side effects and adjust treatment as necessary.
Avoid Clolar (Clofarabine) If
- Avoid use in patients with known hypersensitivity to clofarabine or any of its components.
- Caution or avoidance may be necessary in patients with severe renal or liver dysfunction due to potential alterations in drug metabolism and increased risk of toxicity.
- Generally avoided in pregnant or breastfeeding women due to potential harm to the fetus or infant.
